Axitinib-related osteonecrosis of the jaw

Vinod Patel; Chris Sproat; Jerry Kwok; Nikki Tanna

doi:10.1016/j.oooo.2017.08.003

King's College London

King's main site

Research portal

Axitinib-related osteonecrosis of the jaw

Research output: Contribution to journal › Article › peer-review

Vinod Patel, Chris Sproat, Jerry Kwok, Nikki Tanna

Original language	English
Journal	Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics
Early online date	18 Aug 2017
DOIs	https://doi.org/10.1016/j.oooo.2017.08.003
Accepted/In press	1 Aug 2017
E-pub ahead of print	18 Aug 2017
Additional links	Link to publication in Scopus

King's Authors

Abstract

Tyrosine kinase inhibitors (TKIs) are oral chemotherapy drugs used primarily to treat leukemias, renal cell carcinomas, gastrointestinal stromal tumors, and neuroendocrine tumors. Within this group, a number of drugs have already been implicated in jaw necrosis. Axitinib (Inlyta) is a novel TKI currently licensed for the treatment of renal cell carcinoma. We report the first case, to our knowledge, of jaw necrosis solely related to this medication and review the literature surrounding TKIs and their implication in osteonecrosis of the jaw.

View graph of relations

King's College London - Homepage

Axitinib-related osteonecrosis of the jaw

King's Authors

Abstract

By the same authors

With some of the same researchers

From the same journal